The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
March 9 (Reuters) - Xenon Pharmaceuticals (XENE.O), opens new tab said on Monday its experimental epilepsy drug met the main goal of showing a statistically significant reduction in focal onset ...
Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more than 50% for some patients as it looks to position itself to become the ...
Xenon Pharmaceuticals Inc. XENE-Q stock soared Monday after the Canadian drug developer reported better-than-expected results from a late-stage human trial for its epilepsy treatment. Burnaby, ...
Rick Bishop got a black Labrador named Sailor in 2017 to help deal with the epileptic seizures he had multiple times daily. Sailor hasn’t had much to do since the rural Pennsylvania-based retiree ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Connecticut-based Braidwell sold 1,779,953 Xenon Pharmaceuticals shares in the fourth quarter; the estimated transaction value was $74.76 million based on quarterly average prices. Meanwhile, the ...
Xenon Pharmaceuticals is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder treatment. XENE's $555M cash position supports operations into 2027, reducing near ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results